Trial Profile
Early Intervention Trial of Ibrutinib for Patients With Asymptomatic, High-Risk Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Apr 2023
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; DTaP vaccine; Influenza virus vaccine; Pneumococcal 13-valent CRM197 vaccine conjugate
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 31 Mar 2023 Planned primary completion date changed from 31 Dec 2022 to 31 Dec 2023.
- 24 Feb 2022 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.
- 24 Feb 2022 Planned primary completion date changed from 31 Dec 2021 to 31 Dec 2022.